Cantor Fitzgerald initiated coverage of Design Therapeutics with an Overweight rating. The firm expects DT-216P2, the company's lead asset which is designed to elicit improvements in endogenous frataxin production for Friedreich's ataxia, to continue to show clean safety and for some patients to see 20%-30%+ improvement in frataxin protein levels in the blood, the analyst tells investors in a research note. DT-216P2 is the clear near-term value driver of the Design Therapeutics story, the firm says.
